Author

Sara Charmsaz

Royal College of Surgeons Ireland - Cited by 576 - cancer therapeutics

Biography

Sara Charmsaz is a well-known researcher working in Leukaemia Foundation Research Unit, Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006, Australia and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme
BW Day, BW Stringer, F Al-Ejeh, MJ Ting, J Wilson, KS Ensbey, ...Cancer cell 23 (2), 238-248, 2013201
233
2013
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1
BW Day, BW Stringer, MD Spanevello, S Charmsaz, PR Jamieson, ...Neuro-oncology 13 (11), 1202-1212, 2011201
37
2011
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma
BW Stringer, J Bunt, BW Day, G Barry, PR Jamieson, KS Ensbey, ...Oncotarget 7 (20), 29306, 2016201
34
2016
S100β as a serum marker in endocrine resistant breast cancer
Sara Charmsaz, Éamon Hughes, Fiona T. Bane, Paul Tibbitts, Marie McIlroy ...BMC Medicine, 2017201
34
2017
Novel strategies for cancer treatment: highlights from the 55th IACR annual conference
S Charmsaz, DM Collins, AS Perry, M PrencipeCancers 11 (8), 1125, 2019201
30
2019
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer
AL Browne, S Charmsaz, D Varešlija, A Fagan, N Cosgrove, S Cocchiglia, ...Oncogene 37 (15), 2008-2021, 2018201
30
2018
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
S Charmsaz, F Al-Ejeh, TM Yeadon, KJ Miller, FM Smith, BW Stringer, ...Leukemia 31 (8), 1779-1787, 2017201
29
2017
Innovative technologies changing cancer treatment
S Charmsaz, M Prencipe, M Kiely, GP Pidgeon, DM CollinsCancers 10 (6), 208, 2018201
27
2018
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors
S Charmsaz, AM Scott, AW BoydExperimental hematology 54, 31-39, 2017201
25
2017
EphA2 is a therapy target in EphA2-positive leukemias but is not essential for normal hematopoiesis or leukemia
S Charmsaz, K Beckett, FM Smith, C Bruedigam, AS Moore, F Al-Ejeh, ...PloS one 10 (6), e0130692, 2015201
22
2015
Epigenome-wide SRC-1–mediated gene silencing represses cellular differentiation in advanced breast Cancer
E Ward, D Varešlija, S Charmsaz, A Fagan, AL Browne, N Cosgrove, ...Clinical Cancer Research 24 (15), 3692-3703, 202
18
2018
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB
M Periyasamy, AK Singh, C Gemma, R Farzan, RC Allsopp, JA Shaw, ...Oncogene 40 (6), 1077-1090, 2021202
17
2021
Expression and function of the Eph receptor family in leukemia and hematopoietic malignancies: prospects for targeted therapies
S Charmsaz, AW BoydJournal of Leukemia 1, 2013201
12
2013
Eph receptors as oncotargets
S Charmsaz, AW BoydOncotarget 8 (47), 81727, 2017201
6
2017
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic …
D Varešlija, E Ward, SP Purcell, NS Cosgrove, S Cocchiglia, ...Oncogene 40 (7), 1318-1331, 2021202
6
2021
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis
S Charmsaz, B Doherty, S Cocchiglia, D Varešlija, A Marino, N Cosgrove, ...BMC medicine 18 (1), 1-1, 2020202
4
2020
Steroid ligands, the forgotten triggers of nuclear receptor action; implications for acquired resistance to endocrine therapy
R Bleach, SF Madden, J Hawley, S Charmsaz, C Selli, KM Sheehan, ...Clinical Cancer Research 27 (1), 3980-3989, 2021202
4
2021
EphA3 as a target for monoclonal antibody therapy for acute leukemia
EphA as a target for monoclonal antibody therapy for acute leukemiaS Charmsaz, KJ Miller, BW Day, F El-Ajeh, GT Yarranton, CR Bebbington, ...Blood 122 (21), 501-501, 20120
3
2013
An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer
P Borde, N Cosgrove, S Charmsaz, ST Safrany, L YoungCancer gene therapy 30 (), 368-374, 030
2
2023
CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
B Ffrench, E Kashdan, Y Huang, CD Spillane, S Cocchiglia, S Charmsaz, ...Heliyon 9 (1), 030
2
2023

Referred From: https://scholar.google.com.au/citations?user=KuoWEtUAAAAJ&hl=en

Cited by
Citations 576
h-index 12
i10-index 13
Recommended Journals
Open Access Journals